Competition law and policy in the Japanese pharmaceutical sector

著者

書誌事項

Competition law and policy in the Japanese pharmaceutical sector

Akira Negishi, Masako Wakui, Naoko Mariyama, editors

（Kobe University monograph series in social science research / series editor, Takashi Yanagawa）

Springer, c2022

  • : hbk

大学図書館所蔵 件 / 全11件

この図書・雑誌をさがす

注記

Includes bibliographical references and index

内容説明・目次

内容説明

This is the first book published that focuses on competition law and policy in the Japanese pharmaceutical sector. It consists of chapters written and edited by academics who research the industry from various perspectives, including economics, competition law, pharmaceutical regulations, and intellectual property law. Competition policies involving pharmaceutical products attract attention from academics and policymakers worldwide. The pharmaceutical industry is regulated by drug laws that vary from country to country and are affected by differing practices and industrial structures. The book begins by examining drug regulations and trade practices in the industry that are peculiar to Japan and its healthcare system. It then presents the Japanese Antimonopoly Act and cases involving it, and discussions of current competition law issues in the Japanese pharmaceutical industry. The book also discusses innovation and intellectual property and economic analyses of pharmaceutical regulations and drug discovery. The chapters include comparative studies on Japanese regulations vs. those in the European Union and the United States. Japan is one of the biggest pharmaceutical markets in the world. With this in mind, the book provides "one-stop shopping" for anyone interested in pharmaceutical regulations in the country. Covering the basics but extending to in-depth explorations of complex problems, this book appeals not only to students and academics, pharmaceutical companies and regulators, but also to those dealing with real-world policy issues that encompass competition policy, intellectual property, and pharmaceutical regulation. Chapter 11 is available open access under a Creative Commons Attribution 4.0 International License via link.springer.com

目次

I. Healthcare and pharmaceuticals: Innovation and regulation in Japan Building a Sustainable Medical Care Delivery System and Competition Policy Goro Sato Drug Regulation in Japan Yutaka Tejima Collaboration between the Patent System and Pharmaceutical Regulations for Drug-Discovery Innovation in Japan Takeshi Maeda Corruption and Conflict of Interest in the Pharmaceutical Market in Japan Masako Wakui II. The Japanese Antimonopoly Act and its relation to the pharmaceutical industry Antimonopoly Act and Its Application to the Pharmaceutical Industry in Japan Akira Negishi Horizontal Cooperation and Alliances among Pharmaceutical Companies in the Japanese Antimonopoly Act Shingo Seryo Merger Regulations in the Pharmaceutical Industry in Japan Kuninobu Takeda Pay-For-Delay Agreements in Japan Naoko Mariyama Non-Challenge Clause in the Pharmaceutical Sector and the AMA Thomas K. Cheng Will Authorised Biologics Deter Biosimilars?: Utilising JFTC's Expertise in Drug Pricing Takanori Abe III. An economic Analysis of the pharmaceutical industry and trade practices in Japan The Pharmaceutical Industry in Japan: A History of Its Development Kenta Nakamura Trade Practices in the Japanese Pharmaceutical Market: Modelling and Simulation of Improvement Policies Konosuke Noto

「Nielsen BookData」 より

関連文献： 1件中  1-1を表示

詳細情報

ページトップへ